PHOENIX — Tezepelumab consistently reduced exacerbations in adults and adolescents with severe asthma across all seasons, according to NAVIGATOR trial results presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Results from the NAVIGATOR phase 3 trial contributed to the FDA approval of tezepelumab (Tezspire, Amgen/AstraZeneca) — a human monoclonal antibody that targets thymic stromal lymphopoietin — as an add-on maintenance treatment of adults and children aged 12 years and older with severe asthma.
“Seasonal variations in the frequency